AACR 2022 | An insight into MGIP and its role in the development of precursor conditions
Annie Cowan
• 10 Apr 2022
Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the PROMISE study (NCT03689595) in which high-risk individuals were screened to determine their risk of developing precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma. Ms Cowan explains how mass spectrometry was used to identify a novel condition known as monoclonal gammopathy of indeterminate potential (MGIP), and concludes by highlighting the importance of using MGIP to better understand the biology of disease and prevent progression. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
